BioStrategies LC is a biotech company focused on the development of innovative protein-based therapeutics for human health and veterinary applications.  The company has received multiple grant awards from NIH and other federal and state agencies and received the prestigious SBA Tibbett’s Award in 2012 for innovative research excellence in the national Small Business Innovative Research Program (SBIR).  This award recognized the company’s pioneering research to develop novel enzyme replacement therapeutic (ERT) technology, which employs biotechnology approaches for production of the human enzyme in a safe, low cost plant-based production system for the rare genetic condition, Gaucher’s Disease.  This innovative technology was the foundation for Protalix’ plant-produced ERT drug for Gaucher’s, Elelyso, which in 2012 became the first plant-produced biologic drug to receive FDA approval and is currently marketed worldwide by a partnership between Pfizer and Protalix. BioStrategies continues to bring novel technologies to therapeutics for rare disease with the development of new lectin-based protein delivery systems.   The company’s lectin-ERT fusion proteins are designed to increase ERT drug effectiveness by enhancing delivery to cells and tissues of the body that are not treated adequately by existing ERT drugs and drug delivery mechanisms.